Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086190 · ClinicalTrials.gov registry record · Phase 3
Study of Antidepressants in Parkinson's Disease
A Phase 3 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
NCT00086190 is a Phase 3 study that has completed, run by University of Rochester. The registered enrollment target is 115 participants.
The verdict
NCT00086190, a Phase 3 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease such as tremor, stiffness, slowness, and balance.
Interventions
- OTHER placebo
- DRUG venlafaxine
- DRUG paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086190
The ClinicalTrials.gov registry entry for NCT00086190 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00086190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086190 about?
NCT00086190 is a clinical study titled "Study of Antidepressants in Parkinson's Disease". The purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease such as tremor, stiffness, slowness, and balance.
What is the current status of trial NCT00086190?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2005-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00086190?
The interventions under investigation include: placebo (OTHER), venlafaxine (DRUG), paroxetine (DRUG).
Who is sponsoring clinical trial NCT00086190?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.